LTV-HEXIM1 (147-164, LTV-BR

General Information


DRACP ID  DRACP01938

Peptide Name   LTV-HEXIM1 (147-164, LTV-BR

Sequence  LTVSPWYGCGQLGKKKHRRRPSKKKRHW

Sequence Length  28

UniProt ID  O94992 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
OPM-2 Plasma cell myeloma; Multiple myeloma Carcinoma 30%Killing=50 µM CellTox cytotoxicity assay 30 min 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  CHO-K1: 0%Killing=50 µM; HFF: 10%Killing=50 µM; WI-38: 5%Killing=50 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01938

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C154H249N53O34S

Absent amino acids  ADEFIMN

Common amino acids  K

Mass  390082

Pl  12.16

Basic residues  12

Acidic residues  0

Hydrophobic residues  5

Net charge  12

Boman Index  -9471

Hydrophobicity  -167.14

Aliphatic Index  38.21

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  12490

Absorbance 280nm  462.59

Polar residues  8

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 26734838

Title  Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy

Doi 10.18632/oncotarget.6794

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_12680

DRACP is developed by Dr.Zheng's team.